News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Genentech, Inc. (JOBS), Biogen Idec, Inc. (Massachusetts)'s Rituxan Meets Goal in Late Stage Leukemia Trial
October 7, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SOUTH SAN FRANCISCO, Calif. -Genentech Inc. and Biogen Idec Inc. said Tuesday their cancer drug Rituxan slowed the progress of chronic lymphocytic leukemia in a late stage clinical trial, meeting its primary goal.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
MORE ON THIS TOPIC
Cancer
Exelixis’ Kinase Blocker Sets ‘New Survival Bar’ in Third-Line Colorectal Cancer, Opening Road to FDA
October 21, 2025
·
2 min read
·
Tristan Manalac
Lung cancer
Akeso, Summit’s PD-1/VEGF Blocker ‘Firmly’ Beats Expectations With Encouraging Survival Data
October 20, 2025
·
2 min read
·
Tristan Manalac
REGULATORY
Webinar: Shifting Risk | Biopharma in an Age of Deregulation
October 16, 2025
·
1 min read
·
BioSpace Insights
IN PARTNERSHIP WITH PII
Work Smart, Build Trust: Connecting Technology, Patient Compliance and Data Processing
October 16, 2025
·
1 min read
·
BioSpace Insights
